TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript
Transcode Therapeutics Inc RNAZ
$4.70
▼ -12.15%
($-0.65)
Open
$5.29
Prev Close
$5.35
Day Range
$4.70 – $5.45
52W Range
$3.82 – $20.99
Market Cap
$4.47M
Beta
1.30
EPS (TTM)
$-45.07
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-04-28 |
| Shares Out. | 950,000 |
| Website | transcodetherapeutics.com/ ↗ |
| Phone | 13026587581 |
Transcode Therapeutics Inc is a publicly traded company under the ticker symbol RNAZ on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2025-06-01)